A polyamine-centric, blood-based metabolite panel predictive of poor response to CAR-T cell therapy in large B cell lymphoma

Anti-CD19 chimeric antigen receptor (CAR) T cell therapy for relapsed or refractory (r/r) large B cell lymphoma (LBCL) results in durable response in only a subset of patients. MYC overexpression in LBCL tumors is associated with poor response to treatment. We tested whether an MYC-driven polyamine...

Descripción completa

Detalles Bibliográficos
Autores principales: Fahrmann, Johannes F., Saini, Neeraj Y., Chia-Chi, Chang, Irajizad, Ehsan, Strati, Paolo, Nair, Ranjit, Fayad, Luis E., Ahmed, Sairah, Lee, Hun Ju, Iyer, Swaminathan, Steiner, Raphael, Vykoukal, Jody, Wu, Ranran, Dennison, Jennifer B., Nastoupil, Loretta, Jain, Preetesh, Wang, Michael, Green, Michael, Westin, Jason, Blumenberg, Viktoria, Davila, Marco, Champlin, Richard, Shpall, Elizabeth J., Kebriaei, Partow, Flowers, Christopher R., Jain, Michael, Jenq, Robert, Stein-Thoeringer, Christoph K., Subklewe, Marion, Neelapu, Sattva S., Hanash, Sam
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9729795/
https://www.ncbi.nlm.nih.gov/pubmed/36384092
http://dx.doi.org/10.1016/j.xcrm.2022.100720

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9729795/
https://www.ncbi.nlm.nih.gov/pubmed/36384092
http://dx.doi.org/10.1016/j.xcrm.2022.100720

Ejemplares similares